---
schema_version: "secwatch.filing_event.v1"
accession: "0000944809-22-000023"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:48:39.285992+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q1 net loss $55.4M; completes ModeX acquisition for $300M and GeneDx sale

## Summary
- Q1 consolidated revenue $329.2M (down from $545.2M); net loss $55.4M ($0.08) vs net income $31.1M ($0.05) prior year.
- Diagnostics revenue $286.6M (down from $507.0M) due to lower COVID-19 testing: 2.0M tests vs 4.1M YoY.
- Acquired ModeX Therapeutics for $300M in OPKO common stock; Dr. Elias Zerhouni named President and Vice Chairman.
- Closed sale of GeneDx to Sema4 for ~$322M upfront (cash + stock) plus up to $150M in milestones.
- Pfizer launched NGENLA in Germany/Japan; OPKO earned $85M milestones. RAYALDEE launched in Germany by Vifor.

## SEC filing metadata
- accession: 0000944809-22-000023
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000094480922000023/0000944809-22-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000094480922000023/opk-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000944809-22-000023
- JSON: https://secwatch.observer/filing/0000944809-22-000023.json
- Plain text: https://secwatch.observer/filing/0000944809-22-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.